Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beleave Inc BLEVF

Beleave Inc is a vertically integrated Canadian cannabis company. It operates streamlined facilities throughout Canada to cultivate high quality cannabis flower, oil and extracts with funded capacity more than 150,000 kilograms per year. Fully licensed to cultivate and sell medical and recreational cannabis, it is leading the way through research partnerships with universities to bridge the gap between science and tradition and to develop pharma-grade extracts and derivatives. The company is currently developing new product lines as the recreational market is expected to allow for food and beverage-based cannabis products.


GREY:BLEVF - Post by User

Comment by Can4realon Feb 22, 2020 1:46pm
115 Views
Post# 30721318

RE:RE:PLOT TWIST: Big boys fall & small players thrive!

RE:RE:PLOT TWIST: Big boys fall & small players thrive!

I just want to make sure you understand before you make that statement.  You do understand that if you account for biological assets correctly, revenues are supposed to equal your cost of sales since you cannabis inventory is measured at selling price less cost to sell. Income on the biological asset is recognized as it grows as it's measured at fair value.  Most retail investors dont understand biologocal asset accounting which is quite complex.  Even most accountants dont understand biological asset accounting lol. 

The number which everyone should be looking at is the impairment on their inventory. Hopefully there isn't a large write down on the next earnings as their was in the previous quarter. 

<< Previous
Bullboard Posts
Next >>